|1.||Leedom, J: 1 article (01/2000)|
|2.||Bassiakos, Y: 1 article (01/2000)|
|3.||Batts, D: 1 article (01/2000)|
|4.||Timpone, J: 1 article (01/2000)|
|5.||Para, M: 1 article (01/2000)|
|6.||Reichman, R C: 1 article (01/2000)|
|7.||Fischl, M A: 1 article (01/2000)|
|8.||Demeter, L M: 1 article (01/2000)|
|9.||Powderly, W: 1 article (01/2000)|
|10.||Resnick, L: 1 article (01/2000)|
|1.||AIDS Dementia Complex
|2.||HIV Infections (HIV Infection)
03/01/1996 - "Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections."
02/01/1995 - "Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. "
02/01/1995 - "Twenty patients were enrolled in a phase I clinical trial of atevirdine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), given in combination with zidovudine for treatment of human immunodeficiency virus type 1 (HIV-1) infection. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
01/01/2000 - "Two open label, phase I studies conducted by the adult AIDS Clinical Trials Group (ACTG) in which atevirdine was administered every 8 h with weekly dosage adjustments to attain targeted trough plasma atevirdine concentrations. "
08/01/1993 - "These data suggest that the interaction of atevirdine with HIV-1 RT is different than that of other nonnucleoside RT inhibitors and that combinations of atevirdine and zidovudine may be useful in patients with AIDS who have initially received monotherapy with zidovudine."
|1.||RNA-Directed DNA Polymerase (Reverse Transcriptase)